Enhanced Chemo‐Immunotherapy Strategy Utilizing Injectable Thermosensitive Hydrogel for The Treatment of Diffuse Peritoneal Metastasis in Advanced Colorectal Cancer

Abstract

Patients with colorectal cancer (CRC) and diffuse peritoneal metastasis (PM) are not eligible for surgical intervention. Thus, palliative treatment remains the standard of care in clinical practice. Systemic chemotherapy fails to cause drug accumulation at the lesion sites, while intraperitoneal chemotherapy (IPC) is limited by high clearance rates and associated complications. Given the poor prognosis, a customized OxP/R848@PLEL hydrogel delivery system has been devised to improve the clinical benefit of advanced CRC with diffuse PM. This system is distinguished by its simplicity, security, and efficiency. Specifically, the PLEL hydrogel exhibits excellent injectability and thermosensitivity, enabling the formation of drug depots within the abdominal cavity, rendering it an optimal carrier for IPC. Oxaliplatin (OxP), a first‐line drug for advanced CRC, is cytotoxic and enhances the immunogenicity of tumors by inducing immunogenic cell death. Furthermore, OxP and resiquimod (R848) synergistically enhance the maturation of dendritic cells, promote the expansion of cytotoxic T lymphocytes, and induce the formation of central memory T cells. Moreover, R848 domesticates macrophages to an anti‐tumor phenotype. OxP/R848@PLEL effectively eradicates peritoneal metastases, completely inhibits ascites production, and significantly prolongs mice lifespan. As such, it provides a promising approach to managing diffuse PM in patients with CRC without surgical indications.

Targeting SUMOylation with an injectable nanocomposite hydrogel to optimize radiofrequency ablation therapy for hepatocellular carcinoma

“…It undergoes phase transition to form a drug-loaded gel depot for sustained drug release upon in vivo administration. Moreover, PLEL hydrogels effectively prolong drug retention time [ 25 , 26 ]. Nevertheless, the poor solubility of small-molecule drugs makes it difficult to achieve a uniform dispersion within hydrogels.…”

The combination of IL-2 nanoparticles and Palbociclib enhances the anti-tumor immune response for colon cancer therapy

“…Furthermore, activated CD8 + T cells secrete IFN-γ and TNF-α, initiating a cascade of inhibitory immune responses against the tumor. Conversely, TGF-β hinders pro-inflammatory cells and Th cells while promoting Treg cells ( 35 , 36 ). Illustrated in Figures 3E–I , is an escalation in IFN-γ and TNF-α secretion post-combination therapy, indicating a heightened immune response of CD8 + T cells.…”

Hydrogels as local depots for on-demand therapeutic delivery: potential therapeutic approaches for tumor metastasis

“…Upon local injection, the hydrogel exhibits sustained release of the drugs that are cytotoxic and enhance the immunogenicity of tumors by inducing immunogenic cell death. 135…”